Lumos Pharma, Inc. (LUMO): Price and Financial Metrics

Lumos Pharma, Inc. (LUMO): $1.65

0.12 (-6.78%)

POWR Rating

Component Grades








Add LUMO to Watchlist
Sign Up

Industry: Biotech




#195 of 347

in industry

LUMO Price/Volume Stats

Current price $1.65 52-week high $4.55
Prev. close $1.77 52-week low $1.37
Day low $1.55 Volume 83,600
Day high $1.87 Avg. volume 26,092
50-day MA $2.43 Dividend yield N/A
200-day MA $2.94 Market Cap 13.39M

LUMO Stock Price Chart Interactive Chart >

Lumos Pharma, Inc. (LUMO) Company Bio

Lumos Pharma, Inc. operates as a biopharmaceutical company. The Company discovers, develops, and commercializes therapeutics for patients and families living with rare diseases. Lumos Pharma operates worldwide.

LUMO Latest News Stream

Event/Time News Detail
Loading, please wait...

LUMO Latest Social Stream

Loading social stream, please wait...

View Full LUMO Social Stream

Latest LUMO News From Around the Web

Below are the latest news stories about LUMOS PHARMA INC that investors may wish to consider to help them evaluate LUMO as an investment opportunity.

Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

Webinar to be Held December 6, 2023 at 1:30pm ESTAUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to discuss topline results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials in greater detail. Management will be joined by three esteemed thought leaders in th

Yahoo | November 21, 2023

Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November

AUSTIN, Texas, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the Company will participate in the Piper Sandler 35th Annual Healthcare Conference being held November 28th – 30th in New York City. Lumos Pharma management will present and host one-on-one meetings at the conference. Piper Sandler 35th Annual Healthcare Conference: November 28th – 30th Title:Lumos Pharma Fi

Yahoo | November 20, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a hot topic on Wednesday and we're starting the morning with a breakdown of the biggest ones.

William White on InvestorPlace | November 8, 2023

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

-- Phase 2 Data for Potentially the First Oral Therapeutic for PGHD Met All Primary and Secondary Endpoints with Supportive Evidence to Advance to Phase 3 – -- OraGrowtH210 Trial Results Show LUM-201 Dose of 1.6 mg/kg Achieves AHVs of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Consistent with Historical Growth Rates for Moderate PGHD Population – -- OraGrowtH212 Data Confirm Unique Pulsatile Mechanism of Action of LUM-201and Demonstrate Closer to Normal Physiological Growth Hormone Levels

Yahoo | November 7, 2023

Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints

Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3 6 & 12 mo AHV ANCOVA Model Terms: treatment, Age at dose 1, Sex, Baseline HT SDS, Baseline BMI SDS, Baseline IGF-1 SDS, LUM-201 PEM, Baseline BA Delay, HT SDS-MPH SDS Bars represent Least Squares Mean (LSM), Error bars represent the Standard Error of LSM OraGrowtH210 Results Show LUM-201 Dose of 1.6 mg/kg Achieves Annualized Height Velocities (AHV) of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Comparable to Growth

Yahoo | November 7, 2023

Read More 'LUMO' Stories Here

LUMO Price Returns

1-mo -33.73%
3-mo -37.50%
6-mo N/A
1-year -48.76%
3-year -83.05%
5-year -87.27%
YTD -48.11%
2023 -11.91%
2022 -47.91%
2021 -80.59%
2020 56.83%
2019 66.45%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!